drugset / Trial / NCT06336395
Ma-Spore ALL 2020 Study
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of this trial is to improve the overall survival rate of children and young adult with B-lineage acute lymphoblastic leukemia (B-ALL) in Singapore and Malaysia in the context of a multicenter cooperative trial using a risk-stratified therapy.
Timeline
- Start
- 2020-03-04
- Primary completion
- 2030-03
- Completion
- 2030-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxorubicin | Other / unclassified | — | Intravenous |
| Subject | Fludarabine | Small molecule | — | Intravenous |
| Subject | Imatinib | Small molecule | — | Oral |
| Subject | Rituximab | Monoclonal antibody | — | Intravenous |
| Subject | dasatinib anhydrous | Small molecule | — | Oral |
| Background | Asparaginase Erwinia chrysanthemi | Protein / enzyme biologic | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Background | Cytarabine | Small molecule | — | Subcutaneous |
| Background | Dexamethasone | Small molecule | — | Oral |
| Background | L-asparaginase | Protein / enzyme biologic | — | Intramuscular |
| Background | MERCAPTOPURINE ANHYDROUS | Small molecule | — | Oral |
| Background | Methotrexate | Small molecule | — | Oral |
| Background | Pegylated asparaginase | Unknown | — | Intravenous |
| Background | Prednisolone | Other / unclassified | — | Oral |
| Background | Thioguanine | Small molecule | — | Oral |
| Background | Vincristine | Small molecule | — | Intravenous |